Australian biotech sues GlaxoSmithKline for $325M

Biota Holdings is suing GlaxoSmithKline over the drug giant's alleged failure to support the smaller company's flu drug, Relenza. GlaxoSmithKline holds the license to develop and commercialize the drug, which Biota claims would have captured 40 percent market share with proper support. Relenza currently has about 5 percent of the flu market. That alleged lack of market support cost Biota up to $325 million, the company claims.

- read this story from Asia Pulse for more

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.